Precision medicine trial opens for rare adult and paediatric cancers

Description

Cancer Research UK, The University of Manchester and Roche Products Ltd (‘Roche’), today (Wednesday 23rd), announce that they have opened a multi-drug, precision medicine trial for people with rare cancers who need more treatment options.

The trial is set up to recruit both paediatric and adult patients, with any rare cancer type and is one of very few precision medicine platform trials in the world targeting these populations.

The DETERMINE* trial aims to find out whether existing drugs, including those which are licensed for more common types of cancer, could also benefit patients with rare cancer types that the drug isn’t currently licensed for.